X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With the new funding from the Foundation, Nanite will work on initially developing polymer nanoparticles that can accurately deliver mRNA therapies to the lung while potentially better resisting the thick, sticky mucus that clogs the lungs of patients with CF.
Lead Product(s): m-RNA Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CF Foundation
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 15, 2023
Details:
Under the terms of the partnership, Nanite will design delivery vehicles for genetic medicines to Schwann cells via PNPs, an emerging technology for drug delivery to hard-to-hit targets and to enhance therapeutic efficacy of antisense oligonucleotides in CMT1A.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: CMT Research Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
